SYK Quote, Financials, Valuation and Earnings

Becton Dickinson & has a net margin of 8.48% compared to Stryker's net margin of 5.86%. Stryker's return on equity of 15.22% beat Becton Dickinson &'s return on equity of 6.75%.

Stryker has a consensus price target of $424.43, signalling upside risk potential of 16.71%. On the other hand Becton Dickinson & has an analysts' consensus of $276.77 which suggests that it could grow by 24.23%. Given that Becton Dickinson & has higher upside potential than Stryker, analysts believe Becton Dickinson & is more attractive than Stryker.

Stryker has a beta of 0.946, which suggesting that the stock is 5.393% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.526%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Becton Dickinson & offers a yield of 1.79% to investors and pays a quarterly dividend of $1.04 per share. Stryker pays 40.73% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Becton Dickinson & quarterly revenues of $5.2B. Stryker's net income of $546M is higher than Becton Dickinson &'s net income of $303M. Notably, Stryker's price-to-earnings ratio is 46.86x while Becton Dickinson &'s PE ratio is 37.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.21x versus 3.14x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 8.48% compared to Stryker's net margin of 12.41%. Stryker's return on equity of 15.22% beat Boston Scientific's return on equity of 8.96%.

Stryker has a consensus price target of $424.43, signalling upside risk potential of 16.71%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 21.23%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Stryker has a beta of 0.946, which suggesting that the stock is 5.393% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Boston Scientific quarterly revenues of $4.6B. Stryker's net income of $546M is lower than Boston Scientific's net income of $566M. Notably, Stryker's price-to-earnings ratio is 46.86x while Boston Scientific's PE ratio is 76.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.21x versus 8.46x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 8.48% compared to Stryker's net margin of 28.41%. Stryker's return on equity of 15.22% beat Intuitive Surgical's return on equity of 15.6%.

Stryker has a consensus price target of $424.43, signalling upside risk potential of 16.71%. On the other hand Intuitive Surgical has an analysts' consensus of $632.53 which suggests that it could grow by 32.67%. Given that Intuitive Surgical has higher upside potential than Stryker, analysts believe Intuitive Surgical is more attractive than Stryker.

Stryker has a beta of 0.946, which suggesting that the stock is 5.393% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Stryker's net income of $546M is lower than Intuitive Surgical's net income of $685.7M. Notably, Stryker's price-to-earnings ratio is 46.86x while Intuitive Surgical's PE ratio is 74.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.21x versus 20.66x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 8.48% compared to Stryker's net margin of 26.88%. Stryker's return on equity of 15.22% beat ResMed's return on equity of 25.56%.

Stryker has a consensus price target of $424.43, signalling upside risk potential of 16.71%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 22.6%. Given that ResMed has higher upside potential than Stryker, analysts believe ResMed is more attractive than Stryker.

Stryker has a beta of 0.946, which suggesting that the stock is 5.393% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. Stryker pays 40.73% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than ResMed quarterly revenues of $1.3B. Stryker's net income of $546M is higher than ResMed's net income of $344.6M. Notably, Stryker's price-to-earnings ratio is 46.86x while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.21x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.